LOS ANGELES -- Patients with metastatic melanoma have faced grim prospects: the American cancer society says the five-year survival rate is only 15 percent. That started changing when the FDA approved ...

Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...

Subcutaneous immunotherapy injections for cancer, such as immune checkpoint inhibitors, are an emerging therapy that may replace some traditional intravenous infusions. Common side effects include ...

(Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial ...

Pembrolizumab showed a 44% pathological complete response rate in dMMR colon cancer patients, with a major pathological response in 57%. Minimal severe side effects were observed, with 8% experiencing ...

Keytruda Qlex, a subcutaneous formulation, is FDA-approved for solid tumors in patients 12 and older, offering an alternative to intravenous administration. Study MK-3475A-D77 showed comparable ...